|By PR Newswire||
|February 6, 2014 03:09 PM EST||
SCOTTSDALE, Ariz., Feb. 6, 2014 /PRNewswire/ -- Applied Biologics LLC, an integrated biotechnology company engaged in the development and commercialization of innovative biologic products derived from the placental tissues, is pleased to announce the appointment of Edward Britt as President.
Since early 2013, Mr. Britt has been an active and engaged part of both the board and the Company. Britt continues his work with the Company as President effective January 15, 2014. As President, Britt will direct all facets of a robust integrated biotechnology company—including all development, development services, financing and distribution activities.
"I am honored to have been chosen by the board to lead Applied Biologics into the next exciting era of the Company," said Edward Britt. "Applied Biologics' focus on execution in research, supply chain management, and superior distribution channels has helped to establish us as a leader in placental tissue-derived products. I look forward to working with our executive team, our employees and distribution partners in driving growth for our Company and the entire regenerative medicine technology space."
"Applied Biologics' board of directors is responsible for ensuring the continuity of the Company's senior leadership and that the executive team possesses the experience, skills and character required to achieve the Company's goals. With today's announcement, we enable a smooth transition to a proven executive in Edward Britt, while providing for ongoing guidance and leadership from Jon and Jason, the co-founders. We have the highest degree of confidence that his leadership will further expand Applied Biologics' impressive record of innovation and commercialization of placental-derived products and continued shareholder value creation," said Ian Vasquez, Director of Operations.
Mr. Wakefield will continue to guide the Company's future strategies and direction. "I am very proud of what we have accomplished during my time as President, and speaking on behalf of the Company co-founders, we look forward to being part of the Company's continued success. At its heart, Applied Biologics is a company of innovators and entrepreneurs and I'm excited by the opportunities that lay ahead," Wakefield said. "I want to congratulate Edward on his new role. Having worked with him for the last year in the Company, I have the utmost confidence in Edward and in the rest of the management team that they will continue to drive technical and business innovations, ensuring the growth and future of Applied Biologics. I very much look forward to continuing to work with Edward in his role as President."
About Applied Biologics LLC
Applied Biologics LLC is a global leader in advancing regenerative medicine through the research, translational biotechnology, development and commercialization of placental-tissue derived products, including, but not limited to FloGraft® and XWRAP®. All of our allograft is procured from consenting donors through a scheduled, full-term Caesarean section birth without fetal sacrifice or harm. Amniotic membrane and fluid offer a rich source of native organic cellular components that deserve extensive research to explore their full potential. Immune privilege is a unique characteristic that differentiates this human allograft from other tissue sources. Applied Biologics is focused on optimizing the regenerative potential of this unique allograft. Since 2010, Applied Biologics has been an industry leader in providing innovative amnion-technology for management of soft-tissue defects, orthopedic procedures, sports medicine, chronic wounds, and nerve, ligament and tendon defects. For more information, please visit: www.appliedbiologics.com.
Applied Biologics Forward-looking Statement
This publication may include "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Applied Biologics' management and are subject to significant risks and uncertainties. Applied Biologics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Accordingly, all written or oral forward-looking statements attributable to Applied Biologics, LLC are qualified by this caution.
SOURCE Applied Biologics LLC
Jul. 28, 2016 07:15 PM EDT Reads: 343
Jul. 28, 2016 07:15 PM EDT Reads: 1,225
Jul. 28, 2016 06:45 PM EDT Reads: 1,628
Jul. 28, 2016 06:30 PM EDT Reads: 1,655
Jul. 28, 2016 06:00 PM EDT Reads: 949
Jul. 28, 2016 05:30 PM EDT Reads: 1,858
Jul. 28, 2016 05:30 PM EDT Reads: 2,213
Jul. 28, 2016 05:00 PM EDT Reads: 426
Jul. 28, 2016 04:30 PM EDT Reads: 1,186
Jul. 28, 2016 04:30 PM EDT Reads: 904
Jul. 28, 2016 04:15 PM EDT Reads: 369
Jul. 28, 2016 04:15 PM EDT Reads: 1,773
Jul. 28, 2016 03:45 PM EDT Reads: 1,028
Jul. 28, 2016 03:45 PM EDT Reads: 1,121
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Jul. 28, 2016 03:30 PM EDT Reads: 381